Skip to content

James Hadfield

  • Molecular Biology
  • Director (Innovation) Precision Medicine Labs
  • AstraZeneca UK Ltd
  • 24h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 6913CitationsNumber of citations received by James's publications. Updated daily.

Recent publications

  • Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension

    • Azizan E
    • Poulsen H
    • Tuluc P
    • et al.
    Get full text
  • Introduction to miRNA Profiling Technologies and cross-platform comparison.

    • Aldridge S
    • Hadfield J
    Get full text

Professional experience

Director (Innovation) Precision Medicine Labs

AstraZeneca UK Ltd

April 2018 - Present



University of East Anglia, School of Biological Sciences

September 1992 - July 1995(3 years)

Research interests


I have been running microarrays since 2000 and moved to CRUK to set up a new genomics core. We introduced Illumina seqeuncing to the facility in 2007 and I am one of the two poepl that setup the Google Map for next-gen sequencers ( My lab runs microarrays (Illumina, Affy, Agilent), Ilumina seqeuncing (2xGAIIx and 1xHiSeq), Pyrosequencing, Real-tim PCR, Sanger sequncing. In 2009 we ran 2500 expression arrays for a single project. My main reearch interestes are in the applications of genomics to clinical and high-throughput projects and development of genomic technologies.


Co-authors (708)